Preparation of fluorescent polydopamine nanoparticles with controllable particle size and detection of trypsin
Fluorescent polydopamine nanoparticles are used to detect trypsin by inducing fluorescence quenching with protamine and restoring fluorescence upon trypsin addition, providing a simple and sensitive detection method for trypsin with a detection limit of 6.4 ng/mL.
Patent Information
- Application Number
- CN202010067821.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-01-20
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-01-20
AI Technical Summary
Existing methods for detecting trypsin using existing technologies are limited in effectively addressing the challenges of addressing the challenges of existing technologies are limited in effectively addressing the challenges of existing technologies are not able to provide a simple, highly sensitive, and efficient method for detecting trypsin, which is crucial for diagnosing diseases such as acute pancreatitis and pancreatic cancer.
The development of fluorescent polydopamine nanoparticles (PDNPs) that undergo aggregation-induced quenching upon interaction with protamine, followed by trypsin-induced hydrolysis to restore fluorescence, allowing for a straightforward fluorescence detection method.
This method achieves a detection limit of 6.4 ng/mL with high sensitivity and selectivity, making it suitable for diagnosing trypsin-related diseases with ease and accuracy.
Smart Images

Figure CN111208104B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the application field of fluorescent polydopamine nanoparticles, and in particular to a fluorescence method for detecting trypsin based on aggregation-induced quenching of the fluorescence of polydopamine nanoparticles under the action of protamine. Background Art
[0002] (1) Proteases are proteolytic enzymes that are involved in various biological and physiological processes, including digestion, coagulation, apoptosis, and a range of other cellular activities. Trypsin (TRY), as one of the most important digestive proteases, plays an important role in regulating pancreatic exocrine function. TRY is overexpressed in acute pancreatitis, cystic fibrosis, and pancreatic cancer. Therefore, TRY has been considered a biomarker for the above diseases.
[0003] (2) There are many methods for the determination of trypsin, including enzyme-linked immunosorbent assay, colorimetry, chemiluminescence, electrochemical immunoassay, photoelectrochemistry and fluorescence. Among them, the fluorescence method has the advantages of simplicity, high sensitivity, rapid implementation and real-time detection, making it more attractive and promising. To date, TRY fluorescence detection methods based on gold nanoparticles, conjugated polymer dots and organic dyes have been reported. Most of these methods are designed based on the regulation of TRY on the interaction between fluorescent probes and proteins to induce fluorescence changes through fluorescence resonance energy transfer or internal filtering effects or aggregation in the form of interaction. Therefore, the development of a suitable interaction system between proteins and specific probes is the key to trypsin detection.
[0004] (3) Establish a quantum dot with specific fluorescent properties. Through the rational design of size and surface properties, the interaction between quantum dots and proteins can be realized to achieve adjustable luminescence changes, so that the fluorescence adjusted by the enzymatic cleavage of trypsin changes again. It is expected that a new method for the determination of trypsin through simple mixing operations can be established.
[0005] (4) Dopamine, as a biological neurotransmitter, can be converted into polydopamine (PDA) with adjustable morphology through covalent bonds, hydrogen bonds and π-π interactions. Due to its excellent biocompatibility, PDA has become a new type of biopolymer material used in biomedicine, surface coatings, sewage treatment and other fields. Compared with the common large-sized non-fluorescent polydopamine probe carrier used as a bioanalytical probe, PDA is decomposed into fluorescent polydopamine nanoparticles (F-PDA) by certain controlled synthesis methods and converted into bioanalytical applications. However, there are almost no analytical strategies established for the interaction of F-PDA with biomacromolecules (such as proteins). Summary of the invention
[0006] (1) In view of this, the purpose of the present invention is to restore the fluorescence of PDNPs by adding trypsin to specifically hydrolyze protamine (Pro) bound to PDNPs, thereby establishing a fluorescence method for detecting trypsin, which is simple to operate and has high sensitivity.
[0007] (2) In order to achieve the above object, a method for preparing fluorescent polydopamine nanoparticles with controllable particle size is provided, characterized in that it comprises the following steps: mixing dopamine (DA) and tris(hydroxymethylaminomethane) (Tris) and stirring them to self-polymerize into polydopamine nanoparticles (PDA nanoparticles), then adding H2O2 and NaOH and heating to reflux, and dialyzing the final product with a dialysis bag with a molecular weight cutoff of 3500 Da to obtain fluorescent polydopamine nanoparticles (PDNPs).
[0008] The tris(hydroxymethyl)aminomethane (Tris) was added with HCl to adjust the pH of the solution to 8.5, and the solution was stirred for 20 hours.
[0009] The preparation method is characterized in that PDNPs are prepared after adding H2O2 and NaOH and heating under reflux for 30 min.
[0010] The maximum excitation wavelength of the PDNPs is 340 nm, and the maximum emission wavelength is 435 nm.
[0011] The preparation method of the present invention prepares fluorescent polydopamine nanoparticles (PDNPs).
[0012] The method for detecting trypsin using fluorescent polydopamine nanoparticles of the present invention detects the fluorescence of PDNPs before and after adding trypsin at different concentrations by fluorescence spectrophotometry, and is characterized in that the solution used in the fluorescence spectrophotometry is a mixture of a buffer solution, the fluorescent polydopamine nanoparticles (PDNPs), protamine and trypsin.
[0013] In the buffer solution, PDNPs, protamine, and trypsin solutions, the protamine (Pro) concentration was optimized in the range of 10 to 80 μg / mL and the reaction time of PDNPs, protamine, and trypsin was optimized in the range of 0.1 to 20 min.
[0014] The detection method is characterized in that the optimal Pro concentration is 40 μg / mL and the optimal reaction time is 20 min.
[0015] The detection method is characterized in that the buffer solution is PBS, the buffer solution concentration is 10 mM, and the pH is 8.0. After the trypsin (TRY), PDNPs and protamine solution are mixed, they are incubated at room temperature for 10 minutes and then fluorescence detection is performed.
[0016] The equation of the fluorescence spectrum curve drawn by the fluorescence spectrophotometry is: Y=0.060+4.298X, R 2 =0.99203, Y is (F-F0) / F0, F0 and F are the fluorescence values of PDNPs-Pro before and after the addition of trypsin, respectively; X is the trypsin concentration, the lowest detection limit (LOD) = 6.4 ng / mL; the content of each component in the solution is: the concentration of PDNPs is 0.15 μg / mL, and the concentration of Pro is 40 μg / mL.
[0017] Specifically, the present invention provides a fluorescence method for detecting trypsin based on the fluorescence aggregation-induced quenching system of fluorescent polydopamine nanoparticles under the action of protamine (PDNPs-Pro), characterized in that it includes the following steps: preparing trypsin solutions of different concentrations, adding them to PDNPs-Pro, and detecting the fluorescence of PDNPs-Pro before and after adding trypsin. The reagent configuration operation is simple and the reaction conditions are easy to manipulate.
[0018] (3) The prepared reagents were reacted at room temperature in the dark for 20 minutes, then transferred to a fluorescence spectrophotometer, excited at 340 nm, and the fluorescence intensity was read at 435 nm. The reaction and determination conditions are simple.
[0019] (4) In order to obtain a platform for detecting trypsin based on aggregation-induced quenching of fluorescent polydopamine nanoparticles, the fluorescence change value of PDNPs after adding different concentrations of protamine is preferably detected.
[0020] (5) In view of the above-mentioned prior art, the purpose of the present invention is to provide a new application field of fluorescent polydopamine nanoparticles which is simple to operate, highly sensitive and can effectively measure trypsin.
[0021] (6) In order to achieve the above-mentioned object, the present invention provides a method for quantitative detection of trypsin, which detects trypsin by fluorescence spectrophotometry, characterized in that the solvent in the fluorescence spectrophotometry is a mixture of a buffer solution, PDNPs, Pro and trypsin.
[0022] (7) The beneficial effect of the present invention is that the present invention reacts PDNPs and Pro, PDNPs and Pro undergo aggregation-induced quenching, and then trypsin is added to specifically hydrolyze Pro to restore the fluorescence of PDNPs. By adding trypsin to measure the degree of change in the fluorescence intensity of PDNPs, a fluorescence detection method for the change in the fluorescence signal of PDNPs is established to detect trypsin, and good results are obtained. It is easy to operate and has high sensitivity. The minimum detection limit of trypsin can reach 6.4 ng / mL.
[0023] (8) Other features and advantages of the present invention will be described in detail in the subsequent specific implementation section. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:
[0025] Figure 1 is a transmission electron microscopy picture of PDNPs;
[0026] Figure 2a is the UV spectrum of PDNPs;
[0027] Figure 2b is the fluorescence spectrum of PDNPs;
[0028] Figure 3 is the emission spectrum of PDNPs obtained under excitation wavelengths from 310 nm to 440 nm;
[0029] Figure 4 The results of PDNPs solution under natural light and ultraviolet light irradiation are shown in Figure 1, where a is natural light irradiation and b is 365nm ultraviolet light excitation;
[0030] Figure 5 is the fluorescence intensity spectrum of PDNPs at different pH;
[0031] Figure 6 is the fluorescence image of PDNPs under continuous excitation at 340 nm wavelength for 1 hour;
[0032] Figure 7 It is the spectrum of aggregation quenching of PDNPs fluorescence after adding Pro and fluorescence recovery after adding trypsin;
[0033] Figure 8 It is the fluorescence intensity dot plot of PDNPs with different concentrations of Pro added;
[0034] Fig. 9 It is the transmission electron microscopy photos of the aggregation degree of PDNPs when 30 μg / mL Pro and 40 μg / mL Pro were added, where a is the PDNPs when 30 μg / mL Pro was added, and b is the PDNPs when 40 μg / mL Pro was added;
[0035] Fig.10 is the fluorescence intensity spectrum of PDNPs after adding trypsin with different activities;
[0036] Fig.11is the linear relationship between the fluorescence intensity recovery efficiency of PDNPs and the trypsin concentration;
[0037] Fig.12 This is a comparison chart of the recovery efficiency of PDNPs fluorescence under different interfering substances. DETAILED DESCRIPTION
[0038] (1) The present invention is described in detail below in conjunction with specific implementations and drawings. It should be understood that the specific implementations described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0039] (2) Implementation Example (Feasibility Analysis)
[0040] The samples of the feasibility experiment of this embodiment were prepared by the following steps:
[0041] The following solutions were prepared: Solution 1 was PDNPs; Solution 2 was protamine (Pro); Solution 3 was PDNPs+Pro; Solution 4 was PDNPs+Pro+trypsin. The concentration of PDNPs was 0.15 μg / mL, the concentration of Pro was 40 μg / mL, and the concentration of trypsin was 0.1 μg / mL. The three component solutions were all prepared with phosphate buffer. The concentration of the buffer solution used in the embodiment of the present invention (the buffer solution was composed of Na2HPO4﹒12H2O, NaH2PO4﹒2H2O, and NaCl) was 10 mM, and the pH of the buffer solution was 8.0. The fluorescent polydopamine nanoparticles (PDNPs) are prepared by dissolving 0.05 g dopamine hydrochloride and 0.0606 g tris(hydroxymethyl)aminomethane (Tris) in 40 mL and stirring for 20 h, then adding H2O2 (20wt%, 15 mL) and NaOH (2.5 M, 10 mL) and heating under reflux for half an hour. If necessary, HCl can be added to the tris(hydroxymethyl)aminomethane (Tris) to adjust the pH of the solution to 8.5 during the reaction.
[0042] (3) Testing the PDNPs prepared in this example:
[0043] 1) Figure 1 TEM image of the PDNPs prepared in this embodiment. Figure 1 As shown, the PDNPs particles are evenly distributed with an average size of 4.83 nm.
[0044] 2) Figure 2a The UV-visible absorption spectrum of PDNPs aqueous solution showed a broad absorption band from 200 to 450 nm, indicating that PDNPs contained a lower proportion of 5,6-dihydroxyindole and dopamine units. Figure 2bIt shows that the maximum excitation wavelength and emission wavelength of PDNPs aqueous solution are 340 nm and 435 nm, respectively, which are basically symmetrical.
[0045] 3) Figure 3 This is the emission spectrum of PDNPs under the conditions of excitation wavelength varying from 310 nm to 440 nm. The maximum excitation wavelength of PDNPs is 340 nm, and the maximum emission wavelength is 440 nm. The emission wavelength of PDNPs shows the characteristics of excitation wavelength dependence.
[0046] 4) Figure 4 The PDNPs shown in a in the figure are brown-yellow under natural light and bright blue fluorescence under ultraviolet light (365 nm). Figure 3 b in.
[0047] 5) Figure 5 The fluorescence intensity of the PDNPs prepared in this example in phosphate buffers at different pH values is shown in FIG. Figure 5 As shown, the fluorescence intensity of PDNPs remained relatively stable at pH 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, and 10.0.
[0048] 6) If Figure 6 As shown in the figure, the fluorescence intensity of PDNPs remained stable under continuous excitation at a wavelength of 340 nm for 1 hour, indicating that the prepared polydopamine nanoparticles have stable fluorescence properties and good resistance to photobleaching.
[0049] 7) Figure 7 The fluorescence intensity diagram of PDNPs with a concentration of 0.15 μg / mL prepared in this example before and after adding Pro with a concentration of 40 μg / mL shows that PDNPs undergo obvious fluorescence quenching under the action of Pro.
[0050] 8) If Figure 8 As shown in Figure 2, the gradual increase of Pro caused the PDNPs to gradually quench, and after 40 μg / mL Pro, the fluorescence quenching of PDNPs reached a plateau. Fig. 9 As shown, the introduction of Pro causes PDNPs to aggregate, and the greater the Pro concentration, the more obvious the PDNP aggregation is. This indicates that the addition of Pro causes PDNPs to aggregate and induce a fluorescence quenching system, thereby forming PDNPs-Pro.
[0051] (4) The present invention also provides a method for detecting trypsin activity by fluorescence spectrophotometry, wherein the solvent in the fluorescence spectrophotometry is a mixture of a buffer solution, Pro, trypsin and the above-mentioned PDNPs.
[0052] ① Accurately measure 10 µL of PDNPs solution, 10 µL of Pro and 10 µL of a series of trypsin with different concentrations, add phosphate buffer, keep the total volume at 200 µL, and place the resulting solution in a fluorescence spectrophotometer after 10 min of reaction in the dark. Among them, all component solutions are prepared with phosphate buffer, PDNPs concentration is 0.15 μg / mL, and Pro concentration is 40 μg / mL.
[0053] ② Under the condition of excitation wavelength of 340 nm, read the fluorescence intensity value at emission wavelength of 440 nm. According to the fluorescence intensity data, the fluorescence intensity value of known Pro can be obtained and the standard curve can be drawn.
[0054] ③ In a preferred embodiment provided by the present invention, the content of each component in the solution is specifically as follows: the concentration of PDNPs is 0.15 µg / mL, the concentration of the buffer solution (the buffer solution is composed of Na2HPO4﹒12H2O, NaH2PO4﹒2H2O, and NaCl) is 10 mM, and the pH of the buffer solution is 8.0. Fig.10 The curves in the figure correspond to trypsin concentrations of 0 µg / mL, 0.01 µg / mL, 0.02 µg / mL, 0.03 µg / mL, 0.04 µg / mL, 0.05 µg / mL, 0.06 µg / mL, 0.1 µg / mL, 0.2 µg / mL, 0.3 µg / mL, 0.4 µg / mL, 0.5 µg / mL and 0.6 µg / mL from bottom to top. It can be seen that with the increase of trypsin concentration, the fluorescence intensity of PDNPs gradually increases. Fig.11 The vertical axis is the fluorescence recovery efficiency of PDNPs. As the concentration of trypsin increases, the fluorescence intensity of PDNPs gradually increases. It can be seen from the figure that when the concentration of the tested trypsin is 0-0.06 µg / mL, its concentration has a good linear relationship with the fluorescence recovery value of PDNPs. The linear equation is: Y=0.060+4.298X, R 2 =0.99203,Y=0.060+4.298X,R 2 =0.99203, Y is (F-F0) / F0, F0 and F are the fluorescence values of PDNPs-Pro before and after the addition of trypsin, respectively; x is the trypsin concentration, and the minimum detection limit (LOD) = 6.4 ng / mL.
[0055] ④ The method for measuring trypsin provided by the present invention has good selectivity, such as Fig.12 As shown, only trypsin can restore the fluorescence value of PDNPs-Pro, and other common interferents cannot restore the fluorescence value of PDNPs-Pro.
[0056] ⑤ The method for determining trypsin provided by the present invention determines spiked trypsin in serum, and the spiked recovery rate is 98.0%~109.8% (see Table 1 for details), and the relative standard deviation does not exceed 1.6%, which has good accuracy and reproducibility.
[0057] Table 1 shows the serum spike recovery and relative standard deviation of trypsin determined by this method
[0058]
[0059] ⑥ The above embodiments are only preferred embodiments of the present invention, not all of them. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention.
Claims
1. A method for detecting trypsin using fluorescent polydopamine nanoparticles, wherein the fluorescence of fluorescent polydopamine nanoparticles PDNPs before and after adding trypsin at different concentrations is detected by fluorescence spectrophotometry, characterized in that: The solution used in the fluorescence spectrophotometry is a mixture of a buffer solution, fluorescent polydopamine nanoparticles PDNPs, protamine Pro and trypsin; the fluorescent polydopamine nanoparticles PDNPs are prepared by the following method, and the preparation steps are as follows: dopamine DA and tris(hydroxymethylaminomethane) are mixed and stirred to self-polymerize into polydopamine nanoparticles, then H2O2 and NaOH are added and heated to reflux, and the final product is dialyzed with a dialysis bag with a molecular weight cutoff of 3500 Da to obtain fluorescent polydopamine nanoparticles PDNPs; HCl is added to the tris(hydroxymethylaminomethane) to adjust the solution pH to 8.5, and stirred for 20 hours; H2O2 and NaOH are added and heated to reflux for 30 min to obtain PDNPs; the maximum excitation wavelength of the PDNPs is 340 nm, and the maximum emission wavelength is 435 nm; in the buffer solution, PDNPs, protamine and trypsin solution, the concentration of protamine Pro is 10-80 μg / mL range, and the reaction time of PDNPs, protamine, and trypsin was optimized in the range of 0.1–20 min.
2. The detection method according to claim 1, characterized in that The Pro concentration was selected as 40 μg / mL.
3. The detection method according to claim 1, characterized in that The buffer solution was PBS with a concentration of 10 mM and a pH of 8.
0. After the trypsin TRY, PDNPs and protamine solution were mixed and incubated at room temperature for 10 min, fluorescence detection was performed.
4. The detection method according to claim 3, characterized in that The equation of the fluorescence spectrum curve drawn by the fluorescence spectrophotometry is: Y=0.060+4.298X, R 2 =0.99203, Y is (F-F0) / F0, F0 and F are the fluorescence values of PDNPs-Pro before and after the addition of trypsin, respectively; X is the trypsin concentration, the lowest detection limit (LOD) = 6.4 ng / mL; the content of each component in the solution is: the concentration of PDNPs is 0.15 μg / mL, and the concentration of Pro is 40 μg / mL.
